ERIS LIFESCIENCES share price has zoomed 5% and is presently trading at Rs 1,370.6.
Meanwhile, the BSE HEALTHCARE index is at 44,113.3 (down 0.3%).
Among the top gainers in the BSE HEALTHCARE index today are ALEMBIC PHARMA (up 2.4%) and GRANULES INDIA (up 2.1%).
KIMS (down 6.2%) and FORTIS HEALTHCARE (down 3.2%) are among the top losers today.
Over the last one year, ERIS LIFESCIENCES has moved up from Rs 908.7 to Rs 1,370.6, registering a gain of Rs 461.9 (up 50.8%).
On the other hand, the BSE HEALTHCARE index has moved up from 28,428.9 to 44,113.3, registering a gain of 55.2% during the last 12 months.
The top gainers among the BSE HEALTHCARE index stocks during this same period were Jubilant Pharmova (up 164.4%), SUVEN PHARMACEUTICALS (up 109.3%) and Glenmark Pharma (up 98.5%).
Must See: These Segments are Witnessing Incredible Growth with Modi's Push
The BSE Sensex is at 83,714.3 (down 0.7%).
The top losers among the BSE Sensex today are Asian Paints (down 2.2%) and Tata Motors (down 2.0%). The most traded stocks in the BSE Sensex are HDFC Bank and Tata Steel.
In the meantime, NSE Nifty is at 25,616.8 (down 0.7%). BPCL and Eicher Motor are among the top losers in NSE NIFTY.
Over the last 12 months, the BSE Sensex has moved up from 65,512.1 to 83,714.3, registering a gain of 18,202.2 points (up 27.8%).
ERIS LIFESCIENCES net profit fell 4.5% YoY to Rs 894 million for the quarter ended June 2024, compared to a profit of Rs 937 million a year ago. Net sales rose 54.2% to Rs 7,197 million during the period as against Rs 4,666 million in April-June 2023.
For the year ended March 2024, ERIS LIFESCIENCES reported 6.1% increase in net profit to Rs 3,971 million compared to net profit of Rs 3,742 million during FY23. Revenue of the company grew 19.2% to Rs 20,091 million during FY24.
The current Price to earnings ratio of ERIS LIFESCIENCES, based on rolling 12 month earnings, stands at 47.5.
Equitymaster requests your view! Post a comment on "ERIS LIFESCIENCES Gains 5%; BSE HEALTHCARE Index Down 0.3%". Click here!
Comments are moderated by Equitymaster, in accordance with the Terms of Use, and may not appear
on this article until they have been reviewed and deemed appropriate for posting.
In the meantime, you may want to share this article with your friends!